| 商品名称 | Purevax RCCh |
|---|
| 适用类别 | Veterinary |
|---|
| 治疗领域 | |
|---|
| 通用名/非专利名称 | vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections |
|---|
| 活性成分 | attenuated feline rhinotracheitis herpesvirus (FHV F2 strain);inactivated feline calicivirosis antigens (FCV 431 and G1 strains);attenuated Chlamydophila felis (905 strain) |
|---|
| 产品号 | EMEA/V/C/000092 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Lapsed |
|---|
| ATC编码 | QI06AH |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2005/02/22 |
|---|
| 上市许可开发者/申请人/持有人 | Merial |
|---|
| 人用药物治疗学分组 | |
|---|
| 兽用药物治疗学分组 | Immunologicals for felidae |
|---|
| 欧盟委员会决定日期 | 2014/02/12 |
|---|
| 修订号 | 8 |
|---|
| 治疗适应症 | Active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs and excretion; against Chlamydophila felis infection to reduce clinical signs. Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components. The duration of immunity is 1 year after the last (re-)vaccination. |
|---|
| 适用物种 | Cats |
|---|
| 兽用药物ATC编码 | QI06AH |
|---|
| 首次发布日期 | 2014/02/12 |
|---|
| 最后更新日期 | 2015/01/22 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/purevax-rcch-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/veterinary/EPAR/purevax-rcch |
|---|